Overview

Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The investigators will compare plasma kinetics of two marker drugs in individuals with different genetic variations in the MDR1-gene. The hypothesis is that one group will have higher exposure than the other.
Phase:
Phase 1
Details
Lead Sponsor:
Karolinska Institutet
Treatments:
Digoxin
Fluvoxamine